Germany's Merck Seeks Global Growth In Fertility Drugs And Technologies
This article was originally published in Scrip
The diversified German group Merck KGaA believes demographic patterns for the world's seven billion-plus population bode well for fertility treatments and technologies, and is positioning itself accordingly.
You may also be interested in...
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.
ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.
Novartis’s AI head tells Scrip an open-ended collaboration with Amazon Web Services will ‘transform’ the Swiss major’s global manufacturing operations and distribution centers.